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Parkin (PARK2) is one of the largest genes in the human genome encoding for an 
E3 ubiquitin ligase. Its mutation is the cause of early-onset Parkinson’s disease, but 
recently it is linked to other pathologies including cancer. Parkin acts as a tumor sup-
pressor. It displays a wide neuroprotective activity by promoting the removal of dam-
aged mitochondria via mitophagy and increasing proteasomal degradation of toxic 
substrates. PARK2 primary transcript undergoes to an extensive alternative splicing, 
which enhances transcriptomic diversification and protein diversity in tissues and 
cells. To date, GenBank lists 26 human PARK2 transcripts corresponding to 21 dif-
ferent alternative splice variants. These transcripts show different expression patterns 
and encode for proteins with different functions, molecular weight and isoelectric 
point. Previous studies identified inactivating somatic mutations and frequent intra-
genic deletions of PARK2 in human cancers including gliomas (Veeriah et al., 2010). 
Recently, it has been demonstrated that Parkin pathway activation is predictive for 
the survival outcome of patients with glioma (Yeo et al., 2012). 
However, these papers focused on the expression of full length Parkin. In the pre-
sent work we analyzed the expression pattern of Parkin isoforms in astrocytomas of 
different grade and we investigated their functions in a human glioblastoma multi-
forme cell line. Immunoblotting analysis by using two specific antibodies revealed that 
Parkin expression is generally higher in malignant glioblastoma than in less invasive 
astrocytomas, indicating a correlation between expression pattern of Parkin isoforms 
and tumor malignancy. Serum deprivation or treatment with a proteosome inhibitor 
MG132 or with carbonyl cyanide 3-chlorophenylhydrazone (CCCP), an uncoupling 
agent that dissipates the cells mitochondrial membrane potential, increased expres-
sion of 100-55-50 kDa parkin isoforms in glioma cells as compared to controls. These 
results, consistent with other studies, demonstrated a functional connection between 
Parkin expression, mitochondrial integrity and endoplasmic reticulum stress (Bouman 
et al., 2011). Parkin isoforms expression was also confirmed by confocal microscopy 
analysis. These results suggest that the characterization of some PARK2 isoforms may 
be usefull clinically to develop a prognostic tool in patients with brain tumor. 
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